

Symposium

SSPT

Swiss Society of Pharmacology and Toxicology

BIENVENUE
SSPT 2012
WILLKOMMEN

Sponsored by:



Co-Sponsor:



Bristol-Myers Squibb













REGISTRATION
ENREGISTREMENT
T - Z
for participants who have already registered

REGISTRATION
ENREGISTREMENT
P - S
for participants who have already registered

REGISTRATION
ENREGISTREMENT
K - O
for participants who have already registered

REGISTRATION
ENREGISTREMENT
E - J
for participants who have already registered

REGISTRATION
ENREGISTREMENT
A - D
for participants who have already registered

REGISTRATION
ENREGISTREMENT
Sp











Kardiovaskuläre Pharmakologie
<http://www.pharmacology.unibe.ch/SSPT2012/>

Hans-Uwe Simon, MD, PhD
Professor and Chairman

u^b

Institute of Pharmacology
<http://www.pki.unibe.ch/>

PKI





SHM
Hans-Uwe Simon

M 5 H
SHM



- Dronedaronone should not be given to patients with atrial fibrillation and previous or IV heart failure.
- The use of dronedaronone has to be tailored according to the risk profile of the individual patient.
- Updated guidelines on the use of dronedaronone are currently being developed.



INSELSPITAL

UNIVERSITÄTSSPITAL BERN
HOPITAL UNIVERSITAIRE DE BERNE
BERN UNIVERSITY HOSPITAL































Andreas Grüntzig (1939 – 1985) Pioneer in percutaneous coronary intervention (PCI)



9-14-77

9-16-77

10-20-77

Before, during and one-month-after angiograms of Gruentzig's first patient, dilated on September 16, 1977.



 INSELSPITAL





































